anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a method of using the low-temperature ultrahigh-pressure freeze-dried micro-powder technology to process fresh trepang. The technical key points and usages are that: 1. the low-temperature ultrahigh-pressure sterilization: the fresh trepang which is cleaned is arranged in a closed container for keeping for 15 minutes at the pressure of 500 to 1000MPa and within 20 DEG C, so as to inactivate the autolysins, bacteria and virus of the trepang. 2. freeze-drying technology: the sterilized fresh trepang is frozen into ice within 0.5 hour below the minus 5 DEG C, then the ice is sublimed (15 to 20 DEG C) to the water vapor to be discharged under the vacuum condition (40 to 50mm mercury column), so as to control the water content of the trepang after the processing to be lower than 3 percent. 3. micro-powder processing: the trepang after the freeze-drying is carried out with the crude smashing, and then a fluidized bed type air flow smashing machine is adopted to prepare the trepang micro-powder with the diameter of 3 to 5 Mum. 4. The usage of the low-temperature ultrahigh-pressure physical sterilization method has simple production process and low cost, the invention contains no chemical additives, and the bioactive substances of the extracted trepang peptide, acidic polysaccharide, chondroitin sulfate and various substances are high.
Interference with microtubule dynamics in mitosis activates the spindle assembly checkpoint (SAC) to prevent chromosome segregation errors. The SAC induces mitotic arrest by inhibiting the anaphase-promoting complex (APC) via the mitotic checkpoint complex (MCC). The MCC component MAD2 neutralizes the critical APC cofactor, CDC20, preventing exit from mitosis. Extended mitotic arrest can promote mitochondrial apoptosis and caspase activation. However, the impact of mitotic cell death on tissue homeostasis in vivo is ill-defined. By conditional MAD2 overexpression, we observe that chronic SAC activation triggers bone marrow aplasia and intestinal atrophy in mice. While myelosuppression can be compensated for, gastrointestinal atrophy is detrimental. Remarkably, deletion of pro-apoptotic Bim/Bcl2l11 prevents gastrointestinal syndrome, while neither loss of Noxa/Pmaip or co-deletion of Bid and Puma/Bbc3 has such a protective effect, identifying BIM as rate-limiting apoptosis effector in mitotic cell death of the gastrointestinal epithelium. In contrast, only overexpression of anti-apoptotic BCL2, but none of the BH3-only protein deficiencies mentioned above, can mitigate myelosuppression. Our findings highlight tissue and cell-type-specific survival dependencies in response to SAC perturbation in vivo.
Placebo, tablet administered orally once daily for up to 4 years. Participants will also receive standard of care for HRVD.
This project will provide experimental evidence that warm, sensitive, responsive caregiving and structural changes that promote more consistent and fewer caregivers will lead to better physical, mental, social, and emotional development of young children. Structural changes are designed to facilitate a more family-like environment and include smaller group sizes, more consistent caregiving from fewer caregivers, integration by age and disability status, and establishing two daily 60-minute Family Hours in which children and caregivers interact together. The project also attempts to demonstrate that training caregivers can be beneficial to both caregivers and children.

All caregivers and children in three orphanages for children under 4 years old in St. Petersburg, Russia will participate in this study. One orphanage will implement both training and structural changes. A second orphanage will receive training only. The third orphanage will serve as a control, receiving neither training nor structural changes. Caregivers are assessed annually for attitudes to and problems with their jobs; anxiety and depression; coping styles; traditional versus progressive attitudes toward caregiving; sensitivity to children's emotions; values; and perceptions of their own relationships. Children are assessed at 3, 6, 9, 12, 18, 24, 36, and 48 months for physical growth, chronic and acute disorders, functional abilities, and mental, motor, social, and emotional development.
The liver will be retrieved and preserved as in SCS arm. Then, on arrival to the transplant unit, the portal vein and hepatic artery will be cannulated, and the liver perfused with hypothermic oxygenated solution (VitaSmart device) for 2h.
Disclosed is a system for tracking medical data. The system is comprised of a computing environment comprising a processor and a database in data communication with the processor. The computing environment is configured to aggregate medical data from disparate sources, structure the aggregated data into the database and invite, through patient consent, one or more members of a care team to view and provide medical data about a particular patient. The care team includes the particular patient, family members and healthcare professionals. The computing environment is also configured to transmit for display to one or more members of the care team, in a graphical format on an electronic display, a plurality of medical data items in a single screen oriented against a common timeline, wherein the medical data comprises a plurality of pharmaceuticals utilized by a particular patient, and wherein the graphical format indicates changes over time in the utilization of the pharmaceuticals by the particular patient. Each one of the pharmaceuticals is associated with a separate line displayed in parallel to a common timeline to indicate a time period of utilizing the pharmaceutical. The changes are indicated by symbols associated with the lines, wherein the changes include at least one of an increase or decrease of dosage or strength of one of the pharmaceuticals, a replacement of one of the pharmaceuticals with one or more replacement pharmaceuticals, and changing a frequency of taking one of the pharmaceuticals. The changes in the utilization of the pharmaceuticals include a plurality of types of changes, each type of change indicated by a unique symbol.
OBJECTIVES: Best medical therapy (BMT) for acute uncomplicated type B intramural hematoma (TBIMH) is the current treatment guideline, but there is considerable controversy about subsequent clinical course and outcome, which may be associated with a significant failure rate. The purpose of this study was to identify potential risk factors for BMT failure and to develop a risk score to guide clinical decision making.
METHODS: Patients with acute uncomplicated TBIMH between 2011 January and 2020 December were retrospectively studied. Logistic regression was applied to univariately assess potential risk predictors, and multivariable model results were then used to formulate a simplified predictive model for BMT failure.
RESULTS: In a total of 61 patients, the overall rate of BMT failure was 57.4% (35/61), of which 48.6% (17/35) occurred within 28 days of onset. Logistic regression identified maximum descending aortic diameter (HR ​= ​1.99 CI ​= ​1.16-3.40, p ​= ​0.012), initial IMH thickness (HR ​= ​3.29, CI ​= ​1.28-8.46, p ​= ​0.013) and presence of focal contrast enhancement (HR ​= ​3.12, CI ​= ​1.49-6.54, p ​= ​0.003) as potential risk predictors of BMT failure. A risk score was calculated as follows: [Max DTA diameter (mm)∗0.6876 ​+ ​Max IMH thickness (mm)∗1.1918 ​+ ​PAU/ULP ∗1.1369]. Freedom from BMT failure at 1 year was 72% in patients with a risk score ​< ​4.12, compared with only 35.1% in those with a risk score ​≧ ​4.12.
CONCLUSIONS: In a substantial proportion of patients with acute uncomplicated TBIMH, initial BMT failed. Based on the three initial computed tomographic imaging variables, this risk score could help stratify patients at high or low risk for BMT failure and provided additional information for early intervention.
PROBLEM TO BE SOLVED: To obtain a plaster excellent in closely adhering property to a skin, good in feeling in use thereof, high in utilization ratio of a medicine in the plaster and excellent in preservation stability by using a specific supporting material and providing a specific film between the supporting material and a medicine layer. SOLUTION: This plaster is obtained by using an elastic adhesive sheet 1 as a supporting material for the plaster, providing a non-permeable film 2 between the sheet 1 and a medicine layer 3, further laminating a peelable liner 4 on the medicine layer 3. As the flexible adhesive sheet 1, a material having an adhesion property in a part or a whole of one direction is used. Furthermore, a medicine permeable sheet may be arranged at the upper or lower part of the medicine layer. Also, a non-permeable film, a porous liner consisting of a medicine and a porous material, and a peelable liner may be consecutively laminated on the flexible adhesive sheet having an adhesion property. The plaster is advantageous, since the medicine does not escape to the adhering surface during pasting and preserving period thereof.
BACKGROUND: Despite the gold standard treatment for genitourinary syndrome of menopause (GSM) is based on the use of local or systemic estrogen-containing products, the typical long-term side effects of hormonal treatments and, most importantly, the contraindications in patients with history of breast and endometrial neoplasms do limit in some extent its use. As hyaluronic acid and some highly purified botanicals have clearly demonstrated their anti-inflammatory and mucosa-protecting properties, we have tested, in women with GSM, a class II vaginal medical device containing hyaluronate gel and a mucoadhesive active enriched with purified alkylamides from Zanthoxylum bungeanum, triterpenes from Centella asiatica and high molecular weight polysaccharides from Tamarindus indica.
METHODS: Our single-center, open-label, prospective and observational study was conducted on 50 menopausal women enrolled at the Department of Maternal-Fetal Medicine at Umberto I Polyclinic Hospital in Rome, Italy. Gel administration lasted 150 days and was performed daily for the first 12 days and every 48 hours for the remaining 138 days. Clinical evaluations were performed at baseline and after 12, 57 and 150 days. Besides product safety, main outcomes of our study were: 1) vaginal health (by Vaginal Health Index score [VHI]); 2) sexual quality of life (by Female Sexual Distress Scale [FSDS]); and 3) percentage of women declaring regular sexual activity.
RESULTS: The product was safe with no specific adverse events reported. It significantly improved VHI (about 5% after 57 days and 8% after 150 days), FSDS (about 7% after 57 days and 10% after 150 days), and sexual activity (about 20% after 150 days). It also reduced dryness, dyspareunia, burning, itching, and dysuria incidence, respectively by about 18%, 14%, 14%, 27% and 11% after 150 days.
CONCLUSIONS: In women with GSM, the intravaginal administration of a hyaluronate-based gel enriched with purified botanical actives endowed with anti-inflammatory and mucosal-protecting properties, reduced painful sensation during sexual acts and increased regular sexual activity.
Burkitt's lymphoma (BL) is a rare and highly aggressive B-cell non-Hodgkin lymphoma. Although the outcomes of patients with BL have greatly improved, options for patients with relapsed and refractory BL are limited. Therefore, there is an urgent need to improve BL therapeutics and to develop novel drugs with reduced toxicity. In this study, we demonstrated that enolase 1 (ENO1) is a potential novel drug target for BL treatment. We determined that ENO1 was aberrantly upregulated in BL, which was closely related to its invasiveness and poor clinical outcomes. Furthermore, using RNA interference, we demonstrated that ENO1 depletion significantly inhibited cell proliferation and invasion both in vitro and in vivo. Mechanistically, we established that ENO1 knockdown suppressed the PI3K-AKT and epithelial-mesenchymal transition (EMT) signaling pathways by reducing plasminogen (PLG) recruitment, plasmin (PL) generation, and TGF-β1 activation. Addition of activated TGF-β1 protein to the culture medium of shENO1 cells reversed the inhibitory effects on cell proliferation and invasion, as well as those on the PI3K-AKT and EMT signaling pathways. Notably, our research led to the discovery of a novel ENO1-PLG interaction inhibitor, Ciwujianoside E (L-06). L-06 effectively disrupts the interaction between ENO1 and PLG, consequently reducing PL generation and suppressing TGF-β1 activation. In both in vitro and in vivo experiments, L-06 exerted impressive antitumor effects. In summary, our study elucidated the critical role of ENO1 in BL cell proliferation and invasion and introduced a novel ENO1 inhibitor, which holds promise for improving the treatment of patients with BL in the future.
Neonates in this group will receive hypotonic saline with 5% dextrose in 0.45% saline as their maintenance fluid therapy post-surgery. This intervention is being compared to isotonic fluid therapy to evaluate its effectiveness and safety in maintaining electrolyte balance and preventing hypernatremia and edema.
Improved methods for purification and recovery of interferon-beta (IFN-.beta.) and compositions comprising substantially monomeric IFN-.beta. are provided. In one purification method, substantially purified IFN-.beta. or variant thereof is precipitated and then dissolved in a guanidine hydrochloride (HC1) solution. Renaturation of the protein occurs by dilution with a suitable buffer. A similar purification method absent the precipitation step is also provided. Following renaturation of the IFN-.beta., residual guanidine HC1 is removed by diafiltration or dialysis with a pharmaceutically acceptable buffer to prepare pharmaceutical compositions comprising substantially monomeric IFN-.beta..
The object is to improve the elution property of a hardly-soluble substance with a poor absorption property, and to provide a microparticle of such a hardly-soluble substance which is necessary for providing a pharmaceutical preparation having an improved absorption property. Also disclosed is a process for preparation of the microparticle. A microparticle of a hardly-soluble substance which has a specific enteric base material adsorbed on the surface of the substance and has an average particle diameter of 1 to 1000 nm; a microparticle as recited above which further comprises a saccharide; and a process for preparation of the microparticle. The microparticle having an improved elution property can improve the absorption property of a hardly-soluble substance which is hardly absorbable in a human body or the like. The microparticle can be prepared with good efficiency, in a short time, and in a safe manner. It also becomes possible to provide a pharmaceutical preparation having an excellent dispersion stability.
A mixture of at least 6 species of lactic acid bacteria and/or Bifidobacteria is disclosed for use in bakery and medical field. The preferred mixture comprises Streptococcus thermophilus, Bifidobacterium infan- tis, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subsp. bulgaricus. Said mixture is useful for a sourdough, a leavening composition. Baked goods and other food products obtained therefrom are disclosed. These goods have low or no gluten content and are suitable for the integration of the diet of a subject suffering from celiac disease, for decreasing the risk of allergies due to wheat flour al- bumins and globulins, for the treatment of schizophrenic symptoms, in the preparation of products for enteric diet.
Children in the intervention group 1 will be told by the researchers the operation preparation room and the pre-anesthesia process with a picture booklet. It will be ensured that the child and parent are together during the training. The booklet, which is printed separately for each child, will be given to the child and the parent after an average of 15-20 minutes of narration is completed. Simultaneous visual presentation will be made with the content of the picture booklet being explained to the child. While one of the researchers will explain the pre-operative process from the picture booklet, the other will explain the pre-operative preparation process simultaneously with the picture booklet by putting on the bonnet, mask and glove, and with the balloon inflated by the child. In this way, the pictures shown in the picture booklet will be matched with the real environment.
PURPOSE:To obtain a pigment composition for bathing agent composition having excellent dispersibility in water in a bathtub, capable of stably retaining a beautiful milky color even in use for many hours. CONSTITUTION:A pigment composition for bathing agent is obtained by coating the surface of inorganic pigment (titanium oxide having 0.1-1mum average particle diameter) with 2-20 pts.wt. of a polyacrylate having <=500,000 average molecular weight and 10-100 pts.wt. of a polyethylene glycol having >=500 average molecular weight based on 100 pts.wt. of the inorganic pigment. In the production, 100 pts.wt. of the inorganic pigment are blended with 2-20 pts.wt. of the polyacrylate having <=500,000 average molecular weight and 10-100 pts.wt. of the polyethylene glycol having >=500 average molecular weight and 2-33 pts.wt. of water and the mixture system is heated to >= the freezing point of the polyethylene glycol to simultaneously advance dispersion coating treatment and drying operation.
With the prevalence of coronavirus disease 2019, the administration of glucocorticoids (GCs) has become more widespread. Treatment with high-dose GCs leads to a variety of problems, of which steroid-induced osteonecrosis of the femoral head (SONFH) is the most concerning. Since hypoxia-inducible factor 1α (HIF-1α) is a key factor in cartilage development and homeostasis, it may play an important role in the development of SONFH. In this study, SONFH models were established using methylprednisolone (MPS) in mouse and its proliferating chondrocytes to investigate the role of HIF-1α in cartilage differentiation, extracellular matrix (ECM) homeostasis, apoptosis and glycolysis in SONFH mice. The results showed that MPS successfully induced SONFH in vivo and vitro, and MPS-treated cartilage and chondrocytes demonstrated disturbed ECM homeostasis, significantly increased chondrocyte apoptosis rate and glycolysis level. However, compared with normal mice, not only the expression of genes related to collagens and glycolysis, but also chondrocyte apoptosis did not demonstrate significant differences in mice co-treated with MPS and HIF-1α inhibitor. And the effects observed in HIF-1α activator-treated chondrocytes were similar to those induced by MPS. And HIF-1α degraded collagens in cartilage by upregulating its downstream target genes matrix metalloproteinases. The results of activator/inhibitor of endoplasmic reticulum stress (ERS) pathway revealed that the high apoptosis rate induced by MPS was related to the ERS pathway, which was also affected by HIF-1α. Furthermore, HIF-1α affected glucose metabolism in cartilage by increasing the expression of glycolysis-related genes. In conclusion, HIF-1α plays a vital role in the pathogenesis of SONFH by regulating ECM homeostasis, chondrocyte apoptosis, and glycolysis.
Nearly 1 in 3 US adolescents meet the criteria for anxiety, an issue worsened by the COVID-19 pandemic. Untreated adolescent stress and anxiety can adversely affect teenagers' development, education, and physical and mental health. Although stress-management strategies may seem abundant, many are unscalable or inaccessible for today's youth. Slow diaphragmatic breathing reduces stress and anxiety by downregulating the body's stress response, and is a recommended adolescent stress management strategy. Schools are under pressure to support students in reducing stress, yet diaphragmatic breathing practices are rarely used in school settings. The investigators developed and implemented a 5-week curriculum during COVID-era hybrid learning to conduct the first randomized controlled trial of slow diaphragmatic breathing for stress reduction in a US high school setting.
Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. Cohort 1 will receive a prespecified titration scheme; however, adaptive titration schemes may be applied in subsequent cohorts.
PROBLEM TO BE SOLVED: To obtain the subject novel compound that is produced by a microorganism which is parasitic to yew (Taxus cuspidata), has excellent immunosuppressant activity and vascularization inhibitory activity with reduced cytotoxicity. SOLUTION: This novel compound is represented by the formula and has the following chemical and physical properties: description; white and oily; molecular formula; C15 H23 O3 ; mass spectrum; (FABHRMS): the observed value 251.1652, the calculated value: 251.1647 (as C12 H23 O3 ([M+H]-H2 O). This compound is obtained, for example, by aerobically culturing OHHE IA strain isolated from a yew tree in Asahikawa city of Hokkaido Japan (FERM P 16392) in an enriched culture medium. In a preferred embodiment, this microorganism is statically cultured in a liquid culture. In the culture, the pH of the medium is made neutral and the culture is carried out at 15-25 deg.C for 18-24 hours.  The objective compound accumulated in the culture medium is recovered by separating the cell bodies by usual solid-liquid separation means as filtration or centrifugation and extracting the filtrate and the supernatant.
Techniques regarding the management of computational resources based on clinical priority associated with one or more computing tasks are provided. For example, one or more embodiments described herein can regard a system comprising a memory that can store computer-executable components. The system can also comprise a processor, operably coupled to the memory, that executes the computer-executable components stored in the memory. The computer-executable components can include a prioritization component that can prioritize computer applications based on a clinical priority of tasks performed by the computer applications. The clinical priority can characterize a time sensitivity of the tasks. The computer-executable components can also include a resource pool component that can divide computational resources across a plurality of resource pools and can assign the computer applications to the plurality of resource pools based on the clinical priority.
Patients undergoing total knee arthroplasty will be randomized into two groups: control and placebo.

Eache patient will undergo total knee arthroplasty under general anesthesia. Both groups will get the same anesthetic protocal. At the end of surgery, before awakening patients will recieve either a nitroglycerin or placebo patch on their back. Both the participant and the investigator will be blinded to the group assisignment. At the end of surgery both groups will recieve morphine for postoperative pain. In the recovery room they will be given patient controlled analgesia with morphine. An investigator blinded to study assisignment will record pain scores, sedation scores, nauseau and vomiting. Patients will be given patient controlled analgesia for 24 hours and they will be followed for pain levels, morphine use, sedation and nauseau levels. The nitroderm or placebo patch will be removed after 24 hours.
GWI with Postural Orthostatic Tachycardia Syndrome (POTS) GWI veterans who had postural orthostatic tachycardia before exercise and after 2 submaximal exercise stress tests. Postural orthostatic tachycardia was defined by 2015 Consensus as an increase in heart rate of greater than or equal to 30 beats per minute between recumbent (after 5 minutes of rest) and standing up. Standing heart rates were measured every minute for 5 minutes. Postural orthostatic tachycardia was defined if the change in heart rate was more than 30 beats per minute at at least 2 of the 5 standing time points. The average change in heart rate did not have to be above 30. There were 11 GWI POTS subjects.